Heat stability of the Rift Valley Fever Virus Clone 13 live vaccines

Daouam, Samira; Fakri, F.; Ennaji, Moulay Mustapha; Arkam, Amal El; Tadlaoui, Khalid Omari; Oura, Christopher; Elharrak, Mehdi

doi:10.1016/j.trivac.2014.03.001

Cited by 12 publications

(18 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CL13T strain was also more resistant to heating than the CL13 strain. A previous study also confirmed the lack of thermostability of the CL13 vaccine strain [20].…”

Section: Discussionsupporting

confidence: 72%

“…Live attenuated vaccines against RVF have been shown to be more efficient for disease control compared to inactivated vaccines that require an initial course of two vaccinations, followed by an annual booster vaccination [15,16]. The live-attenuated vaccines for RVF that are currently available either have safety problems, as with the Smithburn strain [23] or stability issues, as with the thermolabile CL13 vaccine [20].…”

Section: Discussionmentioning

confidence: 99%

“…It is a mutant strain carrying a large deletion in the nonstructural protein coded by the S segment (NSs), which was isolated from a non-fatal human case of RVF in the Central African Republic [17]. Vaccination using the CL13 strain has been demonstrated to be safe and efficacious in sheep, goats and calves using a single vaccination [18,19].However, a recent study revealed that this vaccine is unstable at temperatures above 22°C, raising the risk associated with using this vaccine in the tropical (hot) countries without strict maintenance of the cold chain during vaccine storage and delivery [20] The objectives of this study were firstly to develop a thermostable CL13 vaccine, through the isolation of a derivative thermostable clone from the original CL13 strain, and secondly to evaluate the safety and efficacy of the new thermostable vaccine through the measurement of vaccine related RVFV, RVFV RNA and neutralizing antibodies in the blood post-vaccination in target species (sheep, goats and cattle).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the Safety and Efficacy of a Live Attenuated Thermostable Rift Valley Fever Vaccine in Sheep, Goats and Cattle

Daouam¹,

Ghzal²,

AE³

2015

J Vaccines Vaccin

View full text Add to dashboard Cite

Rift valley fever (RVF) is a highly significant vector-borne disease causing huge economic loses in livestock (ruminants and camels) and also human fatalities. The disease is endemic in most Sub-Saharan African countries, including West Africa, and has been present in the Middle East since 2010. Vaccination is considered to be the most effective way to prevent and control the expansion of the disease. Currently available attenuated live vaccines for RVF have significant limitations in that they are either thermolabile (CL13 strain vaccine) or causes abortion and teratogenic effects (Smithburn strain vaccine). This study therefore set out to develop a safe and effective thermostable live attenuated RVF vaccine. The existing CL13 vaccine, which is a naturally attenuated strain, was made thermostable through three cycles of heating (56°C) and selection. The resulting candidate vaccine (CL13T) was stable at 4°C for 20 months and shows significantly improved levels of thermostability over the existing CL13 vaccine. A pilot batch of the CL13T vaccine was produced and tested for safety and efficacy in cattle, sheep and goats. The vaccine was found to be safe, with no clinical signs or side effects observed in vaccinated animals, and there was no evidence for circulation of the virus in the blood of animals post-vaccination. On testing for efficacy in cattle, sheep and goats, through the detection of neutralizing antibodies post-vaccination, good levels of neutralizing antibodies were detected for a minimum of one year in sheep and goats, and neutralizing antibodies were detected for least 4 months in cattle. This new thermostable vaccine could represent an efficient tool for the control of rift valley fever in endemic countries. The vaccine also has the potential to be used, along with an appropriate diagnostic test, to differentiate vaccinated from infected animals (DIVA).

show abstract

“…The CL13T strain was also more resistant to heating than the CL13 strain. A previous study also confirmed the lack of thermostability of the CL13 vaccine strain [20].…”

Section: Discussionsupporting

confidence: 72%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the Safety and Efficacy of a Live Attenuated Thermostable Rift Valley Fever Vaccine in Sheep, Goats and Cattle

Daouam¹,

Ghzal²,

AE³

2015

J Vaccines Vaccin

View full text Add to dashboard Cite

show abstract

“…Vaccination is considered to be the most effective way to prevent and control the expansion of the disease. However, the available attenuated vaccines for RVF cause abortions and teratogenic effects (Smithburn strain vaccine) or are thermolabile (CL13 strain vaccine) [ 6 , 9 , 10 ]. An evaluation of efficacy and safety of the CL13 vaccine in ewes at different stages of pregnancy indicated that the vaccine did not induce clinical manifestation of RVF, such as abortion in pregnant ewes, teratogeny in their offspring or pyrexia in vaccinated animals [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Safety and immunogenecity of a live attenuated Rift Valley fever vaccine (CL13T) in camels

Daouam

Ghzal²,

Naouli³

et al. 2016

BMC Vet Res

View full text Add to dashboard Cite

BackgroundRift Valley fever is an emerging zoonotic viral disease, enzootic and endemic in Africa and the Arabian Peninsula, which poses a significant threat to both human and animal health. The disease is most severe in ruminants causing abortions in pregnant animals, especially sheep animals and high mortality in young populations. High mortality rates and severe clinical manifestation have also been reported among camel populations in Africa, to attend however none of the currently available live vaccines against RVF have been tested for safety and efficacy in this species. In this study, the safety and efficacy (through a neutralizing antibody response) of the thermostable live attenuated RVF CL13T vaccine were evaluated in camels in two different preliminary experiments involving 16 camels, (that 12 camels and 4 pregnant camels).ResultsThe study revealed that the CL13T vaccine was safe to use in camels and no abortions or teratogenic effects were observed. The single dose of the vaccine stimulated a strong and long-lasting neutralizing antibody response for up to 12 months.ConclusionThe presence of neutralization antibodies is likely to correlate with protection; however protection would need to be confirmed by challenge experiments using the virulent RVF virus.

show abstract

“…No licensed vaccines are currently available for humans and the live RVFV virus vaccines widely used for livestock in Africa have major drawbacks, including residual virulence, need for high containment during production, and variable immunogenicity [12] . Furthermore, though available as lyophilised products, the bioactivity of these live RVFV livestock vaccines still relies on a cold chain [12] , [13] .…”

Section: Introductionmentioning

confidence: 99%

Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle

Dulal

Wright

Ashfield

et al. 2016

Vaccine

View full text Add to dashboard Cite

Development of safe and efficacious vaccines whose potency is unaffected by long-term storage at ambient temperature would obviate major vaccine deployment hurdles and limit wastage associated with breaks in the vaccine cold chain. Here, we evaluated the immunogenicity of a novel chimpanzee adenovirus vectored Rift Valley Fever vaccine (ChAdOx1-GnGc) in cattle, following its thermostabilisation by slow desiccation on glass fiber membranes in the non-reducing sugars trehalose and sucrose. Thermostabilised ChAdOx1-GnGc vaccine stored for 6 months at 25, 37 or 45 °C elicited comparable Rift Valley Fever virus neutralising antibody titres to those elicited by the ‘cold chain’ vaccine (stored at −80 °C throughout) at the same dose, and these were within the range associated with protection against Rift Valley Fever in cattle. The results support the use of sugar-membrane thermostabilised vaccines in target livestock species.

show abstract

Heat stability of the Rift Valley Fever Virus Clone 13 live vaccines

Cited by 12 publications

References 10 publications

Evaluation of the Safety and Efficacy of a Live Attenuated Thermostable Rift Valley Fever Vaccine in Sheep, Goats and Cattle

Evaluation of the Safety and Efficacy of a Live Attenuated Thermostable Rift Valley Fever Vaccine in Sheep, Goats and Cattle

Safety and immunogenecity of a live attenuated Rift Valley fever vaccine (CL13T) in camels

Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle

Contact Info

Product

Resources

About